Markets
MarketMind AI
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search Stock, IPO, MF
Open in App
IND
USA
IND
IND
×
Close
IND
USA
Overview
Buy Sell Zone
Financials
Charts & Report
Charts and Graphs
Stock Report Pdf
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
(4)
About
Alembic Pharmaceuticals Ltd.
NSE: APLLTD
|
BSE: 533573
|
ISIN: INE901L01018
|
Industry: Pharmaceuticals
US FDA Approval
52 week high
|
Strong Performer, Getting Expensive
1057.1000
26.95
(
2.62
%)
NSE
Nov 16, 2026
15:31 PM
New 52W High today
Volume:
452.1K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Alembic Pharmaceuticals Ltd.
12 Feb 2025
US FDA Approval
52 week high
1057.10
2.62%
Alembic Pharma (BUY): Earnings recovery on normalised Azithromycin base
Buy:
Alembic Pharmaceuticals Ltd.
by
BOB Capital Markets Ltd.
Target: 1032
Target
BOB Capital Markets Ltd.
US and ROW sales grew above our estimates of 5% and 13% respectively, reporting growth of 10% each
Alembic Pharma has gained
27.17%
in the last 3 Months
More from Alembic Pharmaceuticals Ltd.
Recommended
IPO market sees a big-ticket addition as Mahanadi Coalfields prepares to go public
|
16 Nov 2026, 05:01PM
Market closes higher, led by gains in healthcare and FMCG stocks
Trendlyne Marketwatch |
16 Nov 2026, 04:11PM
Earnings Call Transcript - Q1FY21 for Alembic Pharmaceuticals
|
22 Jul 2020